Business Wire

NY-PHILIP-MORRIS-INTL

24.9.2020 21:22:05 CEST | Business Wire | Press release

Share
Science, Data, and Facts Should Unite Decision-Making, Says PMI CEO in Speech at Concordia Summit

André Calantzopoulos, CEO of Philip Morris International (PMI) (NYSE: PM), today delivered high-level remarks at the 2020 Concordia Annual Summit . Calantzopoulos discussed the impact that uncertainty, polarization, hyperpartisanship, and ideology are having on international efforts to overcome pressing global issues. He called for science to be protected from politicization and highlighted the importance of developing open dialogues based on factual scientific objectivity. Calantzopoulos shared PMI’s belief that with the right regulatory encouragement and support from civil society, cigarette sales can end within 10 to 15 years in many countries.

The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster dialogue and enable effective partnerships for positive social impact.

Excerpts of the remarks by André Calantzopoulos follow:

“Reflecting on the state of our world today and the challenges ahead, four words come to mind: Uncertainty . Polarization. Hyperpartisanship. Ideology.

“These words are not new, but with the COVID crisis, they have gained prominence, moving beyond traditionally contentious sectors such as ours and into the mainstream.

“The lockdowns that sent us into our homes earlier this year, the continued uncertainty we all feel, and the immense socioeconomic pressure caused by the pandemic have increased tensions and reinforced the polarization of both private views and the public discourse.

“And while these past months have revealed how much can be accomplished when people work together, the tendency of individuals to put their self-centered impulses ahead of community wellness remains on display.

“Divisiveness—a binary choosing of sides—not only hinders progress but threatens to thwart it.

“Maybe there is no silver-bullet solution—but to focus on respect for and adherence to facts, dialogue, inclusion, and science could help immensely. It is not enough, however, to simply say ‘follow the facts and the science’ and expect progress to unfold. COVID-19 is just the latest example that proves a tragic truth: Science can be, and is being, weaponized to suit narrow agendas. Science and facts are being held hostage—and distorted—by politics, and people are suffering as a result.

“As a society, we are experiencing a confluence of global existential threats. These threats require collective, multilateral discussions and cooperation—and that can only be achieved through a commitment to open dialogue.

“Absent a commitment to factual scientific objectivity—free of agenda-driven politics—we risk the very real and terrifying prospect of vaccine nationalism, an inability to tackle climate change at scale, and a narrowed chance of delivering solutions that create a fairer and more equitable world.

“In a global world, in a global economic and human system, whether we like it or not, there is no solution in isolation. Individual governments or companies alone cannot bring the necessary change. If we want to make the United Nations Sustainable Development Goals a reality, if we want to protect our populations from the pandemic, including implementing a viable vaccine, we must work together. And most important, we must involve the 7.8 billion people on this planet. How do we do this? We tell them what the real problems are—offering the full facts; we propose solutions they can adopt or adapt; and we incentivize them to act in accordance with this new knowledge. We won’t succeed by keeping them in the dark, by confusing them, or by misleading them.

“Being at the helm of the largest multinational tobacco company as it transforms to deliver a smoke-free future, I experience firsthand how detrimental polarization is to making real progress—in this case, progress in eradicating smoking. And, as a reminder, this concerns more than 1 billion men and women who smoke around the world.

“Today, science-based, innovative products that do not involve combustion offer a better alternative for those men and women who would otherwise continue to smoke. To be clear: These products are not risk-free. And the best choice is never to start smoking or to quit tobacco and nicotine altogether. But for those adults who would otherwise continue to smoke, scientifically validated smoke-free products are a much better choice than cigarettes.

“A future in which cigarettes are obsolete is within reach. In fact, with the right regulatory encouragement and support from civil society, we believe cigarette sales can end within 10 to 15 years in many countries. Yes, that’s right: an end to cigarettes within 10 to 15 years in many countries.

“Unfortunately, political agendas and ideology are slowing progress and keeping millions of people uninformed. Rather than holding an evidence-based conversation on how best to regulate these innovative products to help adult smokers leave cigarettes behind, we are often faced with an ideologically driven resistance from some public health organizations and some NGOs. These organizations allow disinformation to appear as legitimate science. They put dogma before data, and they expend more energy on attacking a company than on helping the human beings who should be at the center of the debate.

“Poorly executed scientific studies, skewed results shaped by bias, and misleading media headlines are now the norm.

“What is the result? Many adults who smoke are confused about these better alternatives and so continue to use cigarettes—the most harmful way of consuming nicotine. This is inexcusable. We must ask: Who will take responsibility for denying these adults access to and accurate information about science-backed innovations? Who will be held responsible for the real-world consequences of dogmatic thinking?

“The issues created by uncertainty, polarization, hyperpartisanship, and ideology are not unique to the tobacco sector. From climate change to food security, we need fact-based conversations and a collaborative, multinational, multi-stakeholder approach to deliver real change. The public has a right to decision-making and information based in science. We cannot allow politically driven, well-funded individuals to prevent the world’s citizens from learning about and accessing smart solutions. Whether we are talking about vaccines, carbon emissions, or tobacco harm reduction, we need science, not rhetoric, to inform policies and regulations.

“Science unites. It has the power to open borders and minds and bring progress. It can propel innovation.

“For Philip Morris International, science has changed our company and is transforming our industry. I am proud to come before you today to say that, already, more than 11.2 million people have switched to our main smoke-free product and stopped smoking . Many more have switched to other smoke-free alternatives that are better than continued smoking. This is a profound public health achievement.

“Governments across the world—in Greece, New Zealand, the United Kingdom, and beyond—are beginning to validate the role better alternatives to continued smoking can play. Earlier this year, the U.S. Food and Drug Administration authorized our electronically heated tobacco system, IQOS , as a modified risk tobacco product. In doing so, the agency found that an exposure modification order is ‘appropriate to promote the public health .’

“But a smoke-free future is not yet guaranteed. Ridding the world of cigarettes will require adherence to science, objectivity, collaboration, and a commitment to accelerate information to the people most directly concerned.

“Many years ago, our industry was challenged to create a better alternative to cigarettes. PMI answered that call. We have transformed our entire company to devise and produce scientifically substantiated better products with the aim of delivering a smoke-free future. Science, data, and fact have led us here.

“People who smoke are responding to our efforts. With the right regulations and related information, they could switch out of cigarettes much faster. Let’s put these people—not politics—at the center of policymaking.

“Science secures progress. It secures solutions. It brings hope at a time when global challenges are so great they threaten to overwhelm. We should not allow science to be politicized and polarized.”

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the U.S. under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2020, PMI estimates that approximately 11.2 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 57 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .

# # #

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye